A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Cryopreservation of Oocytes Retrieved from Ovarian Tissue to Optimize Fertility Preservation in Prepubertal Girls and Women

6.2K views

⸱

DOI:

10.3791/61777

⸱

October 23rd, 2020

In This Article

Summary

We propose a protocol for fertility preservation in prepubertal girls and women at risk of premature ovarian insufficiency. It combines ovarian tissue freezing and cryopreservation of oocytes retrieved from ovarian tissue. This strategy improves the safety and optimizes the reproductive potential of fertility preservation, maximizing the chance of childbirth.

Abstract

Human ovarian tissue cryopreservation (OTC) is increasingly used worldwide to preserve female fertility in prepubertal girls and women at risk of premature ovarian insufficiency (POI) in the context of urgent gonadotoxic treatments or ovarian surgery. Fertility preservation is challenging because there is no consensus regarding patient management, preservation fertility strategies, or even technical laboratory protocols, which implies that each procedure must be adapted to the characteristics of the patient profile and its own risk-benefit ratio. During OTC, mature/immature oocytes can be aspirated directly from large/small antral follicles within ovarian tissue samples and/or be released into culture media from growing follicles during ovarian tissue dissection in prepubertal girls and women. In this manuscript, we present a protocol that combines ovarian tissue freezing with the cryopreservation of mature/immature oocytes retrieved from ovarian tissue samples, improving the reproductive potential of fertility preservation. Appropriate collection, handling, and storage of ovarian tissue and oocytes before, during, and after the cryopreservation will be described. The subsequent use and safety of cryopreserved/thawed ovarian tissue samples and oocytes will also be discussed, as well as the optimal timing for in vitro maturation of immature oocytes. We recommend the systematic use of this protocol in fertility preservation of prepubertal girls and women as it increases the whole reproductive potential of fertility preservation (i.e., oocyte vitrification in addition of OTC) and also improves the safety and use of fertility preservation (i.e., thawing of oocytes versus ovarian graft), maximizing the chance of successful childbirth for the patients at risk of POI.

Introduction

The field of fertility preservation has grown over the last two decades due to the increasing number of patients at risk of premature ovarian insufficiency (POI)1,2,3. The current available medical options to preserve fertility are ovarian tissue cryopreservation (OTC)4, oocyte/embryo freezing after ovarian stimulation5, administration of GnRH analogues6, or ovarian transposition7. OTC is a major advance for fertility preservation, particularly in prepubertal girls, where it is the....

Access restricted. Please log in or start a trial to view this content.

Protocol

All women (over 18 years of age) as well as all minor girls and their parents signed an informed consent form to preserve the fertility of the patient at risk of POI. This protocol is considered as a routine ART procedure in our center for fertility preservation. It follows the guidelines of our institutions human research ethics committee.

1. Quality control

  1. Include female age ≤ 38 years, containing circulating anti-mullerian hormone concentration >1 ng/mL and showing the presence of an increased risk of POI due to gonadotoxic treatment. Exclude women eligible for oocyte vitrification for fertility preservation procedure, women....

Access restricted. Please log in or start a trial to view this content.

Results

A total of 81 OTC from 81 female patients have been performed between 2007 and 2020, including 43 prepubertal girls and 38 women. The mean age of female patients (prepubertal girls and women) was 14.21 ± 9.61 years (mean ± standard error). The youngest patient was 5 months old and the oldest was 33.6 years old (Table 1). The mean age of prepubertal girls and women was 6.84 ± 4.81 years old (min–max: 0.5–15.1) and 22.76 ± 5.92 years old (min–max: 14.2–33.6), respectively (Mann-Whitney, p = 3.37 x 10-.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The current manuscript provides a protocol combining ovarian tissue freezing and cryopreservation of oocytes retrieved from ovarian tissue, increasing the potential of fertility in prepubertal girls and women at risk of POI. We strongly recommend performing this protocol before the start of any gonadotoxic therapy in order to optimize the quantity (i.e., number of viable oocytes) as well as the quality (i.e., DNA integrity and cytoplasm competence) of the preserved oocytes, optimizing their safety for clinical use

Access restricted. Please log in or start a trial to view this content.

Disclosures

None of the authors have competing interests.

Acknowledgements

We thank all members of our centers involved in the activity of fertility preservation (Gynecologists, Biologists, Oncologists, and Anatomopathologists). The study was conducted as part of the routine procedures for fertility preservation. No funding was received.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
1 ml disposable syringeCDD1323101/7002655Other material and sizes may also be suitable
21-gauge syringe needleMerckZ192481Other material and sizes may also be suitable
35 mm IVF Petri DishNunc150255Other material and sizes may also be suitable
60 mm IVF Petri DishNunc150270Other material and sizes may also be suitable
90 mm IVF Petri DishNunc150360Other material and sizes may also be suitable
Atraumatic forcepsMedlanePI 299 04Other material and sizes may also be suitable
Continuous Single Culture Complete with HSAIrvine Scientific90165IVF culture medium for follicular fluid collection, COCs incubation, oocyte denudation and oocyte incubation until the vitrification step.
CryotubeThermo Scientific368632Other products may also be suitable
Dimethylsulfoxide (DMSO)MILTENYI BIOTEC SAS170-076-303CryoMACS DMSO 10 (EP)
GT40Air Liquide1,13,517Storage tank
HSV High Security Vitrification StrawIrvine Scientific25251Vitrification straws
Human serum albuminVitrolife10064Other products may also be suitable
Leibovitz L15 mediumEurobioCM1L15000UCulture medium for ovarian tissue collection, transport and tissue dissection
Leibovitz L15 mediumEurobioCM1L15000UCulture medium for freezing solution
Mars-IVF Class II Workstation/L126 IVF DualCooperSurgicalWM1500/6-133-911-121Workstation
Programmable freezerPlanner KRYO 500Kryo 560-16Other equipements may also be suitable
Scissors with sharp straight blades and finely sharpened pointsMedlaneCI 034 03Other material and sizes may also be suitable
StripperCooperSurgicalMXL3-STR-CGROther products may also be suitable
Tips (150µm) for StripperCooperSurgicalMXL3-150Other products may also be suitable
Vitrification KitIrvine Scientific90133Protocols are available at http://www.irvinesci.com/products/90133-so-vitrification-freeze-solutions. Other products may also be suitable

References

  1. Ataman, L. M., et al. Creating a global community of practice for oncofertility. Journal of Global Oncology. 2 (2), 83-96 (2016).
  2. Rivas Leonel, E. C., Lucci, C. M., Amorim, C. A. Cryopreservation of human ovarian tissue: a review. Transfusion Medicine a....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Ovarian Tissue CryopreservationOocyte CryopreservationIn Vitro MaturationOvarian Tissue DissectionOocyte AspirationPremature Ovarian InsufficiencyGonadotoxic TreatmentsOvarian Graft ThawingOocyte Vitrification

This article has been published

Video Coming Soon